Mohammad AskarPublic working copy · medical review pending

Retina · 017

Retinal vascular occlusions: assess vision, perfusion and urgency

A complete teaching review of retinal vein occlusion, with the retained arterial occlusion, giant cell arteritis, neovascular glaucoma and PAMM chapters.

Working copy published: 2026-11-06T03:47:16+01:00. Source, translation and medical checks remain open. Limitations are stated in the text and references. Editorial text version: 2026-11-05 07:38 CET.

Separate macular oedema from retinal ischaemia and neovascularisation. Sudden visual loss needs urgent assessment; suspected acute retinal arterial occlusion requires an emergency stroke pathway and assessment for giant cell arteritis.

Terminology and draft status

Original terms and source questions are retained. Arabic medical translations are working copies; further compound-term WHO UMD checks remain pending. Source, translation and medical approval remain pending.

01Recognise the vascular problem and its urgency

Retinal vein occlusion (RVO) is a common retinal vascular disorder. Retinal arterial occlusion (RAO) has a different emergency pathway; do not combine the two into one prognostic or treatment rule. 1 2 18

The eye findings can prompt assessment of systemic vascular risk. Explain the link without claiming that every RVO causes an imminent stroke or myocardial infarction; the underlying conditions and current symptoms determine urgency. 1 2

In an examination presentation, describe the site of occlusion, visual function, perfusion, oedema and new vessels. Then state the next clinical step: macular treatment, surveillance for neovascularisation, or emergency assessment for arterial ischaemia, giant cell arteritis or painful glaucoma. 1 9 18

02Localise the vein occlusion and judge ischaemia

Central retinal vein occlusion (CRVO) affects venous drainage around the optic nerve head; branch retinal vein occlusion (BRVO) usually occurs at an arteriovenous crossing. Hemiretinal occlusion affects a superior or inferior retinal territory. 1 2

At crossings, a relatively rigid artery and a vein share a connective-tissue sheath. Venous compression, altered flow and endothelial injury can favour thrombosis; the lamina cribrosa is an important anatomical bottleneck in central occlusion, rather than a complete explanation for every case. 1

Assess visual acuity, a relative afferent pupillary defect (RAPD), haemorrhages, cotton wool spots and angiographic non-perfusion together. An RAPD supports substantial asymmetric retinal dysfunction, but is not pathognomonic for ischaemic CRVO; a single acuity cut-off also cannot classify every eye. 1

The historical CVOS definition used more than 10 disc areas of non-perfusion on seven-field fluorescein angiography. This is not interchangeable with the same area in a modern ultra-widefield peripheral image; distinguish macular ischaemia from extensive retinal ischaemia. 1

The RCOphth guideline reports conversion of about 30% of initially non-ischaemic CRVO over 3 years. This is not a 6-month risk estimate or an individual prediction. 1

Choose surveillance by ischaemia, treatment and the possibility of new vessels. RCOphth recommends monthly review initially for significant ischaemia, whereas less ischaemic eyes and eyes after anti-VEGF cessation need their own schedules; a universal mandatory monthly plan for every RVO is inappropriate. 1

Localise the vein occlusion and judge ischaemia
FeatureLess ischaemic CRVOMore ischaemic CRVO
Visual acuityOften better than 0.1 (6/60); not a classifier aloneOften 0.1 or worse, sometimes hand movements; assess the whole eye
RAPDMay be absent or less markedA substantial defect supports asymmetric dysfunction; not pathognomonic
FA/FLA perfusionLess extensive non-perfusion; assess the macula separatelyHistorical CVOS: more than 10 disc areas on seven-field FA; not a universal widefield cut-off
FundusLess marked haemorrhage and venous tortuosity (Tortuositas)Extensive haemorrhage, sometimes Blood & Thunder; neither appearance determines perfusion alone
PrognosisRecovery or recanalisation possible; conversion remains possibleGreater neovascular risk; central prognosis also depends on macular damage

03Investigate vascular risk with a clinical question

RVO is more common with increasing age. Check hypertension, diabetes, lipid disorders and glaucoma; age alone does not replace a clinical risk assessment. 1 2

Measure blood pressure and assess glucose and the medical history; blood count and inflammatory testing may identify relevant systemic disease. Coordinate longer-term risk management with the treating physician. A 24-hour blood-pressure profile or HbA1c may answer a specific clinical question rather than belong to every mandatory panel. 1

Young age, bilateral findings, recurrence, inflammatory signs or a personal or family history of thrombosis justify targeted further assessment. They do not automatically justify every test in the original list: electrophoresis for myeloma or blood disease; syphilis or HIV testing; ACE for suspected sarcoidosis; ANA/ANCA; or protein C/S, antithrombin III, Factor V Leiden, homocysteine and lupus anticoagulant. 1

Routine thrombophilia screening in an isolated RVO is not supported by the RCOphth recommendations. Interpret an abnormal result with the history and specialist advice; one high laboratory value is not a diagnosis of imminent embolism or antiphospholipid syndrome. 1

Carotid Doppler belongs particularly to an arterial or ocular-ischaemia question. The original carotid threshold greater than 70% does not by itself define an identical emergency for every RVO patient; new neurological or retinal arterial symptoms require immediate assessment, while an incidental stenosis needs an appropriate vascular pathway. 1 18

04Use each image to answer a specific question

Fluorescein angiography (FA, also termed FLA) assesses non-perfusion, vessel-wall staining and leakage. Haemorrhage can obscure perfusion; repeat imaging when it will resolve a management question rather than regard every dark area as capillary loss. 1

Optical coherence tomography (OCT) quantifies and localises intraretinal cystoid fluid and subretinal fluid. Inspect the actual B-scans, segmentation and retinal layers alongside visual function; oedema and ischaemia are related but distinct findings. 1 2

A fern-like pattern has been described on en-face structural OCT at the inner nuclear layer (INL), including perivenular PAMM. It is not established here as a frequent, specific fundus autofluorescence (FAF) sign of RVO; FAF does not replace perfusion assessment. 15 16

The initial retrospective series contained 11 selected eyes: 7 had clinically evident RVO and 4 did not. A separate 3-patient series described the pattern in presumed incomplete arterial occlusion; these small selected series cannot establish diagnostic sensitivity, specificity or population prevalence. 15 16

Cotton wool spots (CWS) reflect focal injury and axoplasmic transport disturbance in the retinal nerve fibre layer. They are a finding, not an aetiological diagnosis: consider hypertension, diabetes, severe anaemia or leukaemia, HIV, prior irradiation, connective-tissue disease and vascular occlusion in the clinical context. 1 2

05Treat oedema and neovascular risk separately

Intravitreal treatment blocking vascular endothelial growth factor (anti-VEGF) is a main treatment for vision-impairing RVO-related macular oedema. Aflibercept, ranibizumab and faricimab are options within the relevant label; bevacizumab is used off-label. Confirm the actual product, jurisdiction and regimen rather than transfer a trial schedule to every patient. 2 7 19

SCORE2 randomised 362 CRVO or hemiretinal RVO patients to monthly bevacizumab or aflibercept for 6 months; 348 completed that visit. Mean visual gains were 18.6 and 18.9 letters. The difference was −0.14 letters, with a one-sided 97.5% confidence interval from −3.07 to infinity, meeting the prespecified 5-letter non-inferiority margin. 3

This supports short-term non-inferiority for the tested population and schedule, not equivalence of all regimens, long-term safety or applicability to BRVO. Masking, adherence and the assumptions used for missing outcomes remain important when judging confidence in the result. 3

LEAVO randomised 463 CRVO patients across 3 treatments for 100 weeks. Mean visual gains with ranibizumab, aflibercept and bevacizumab were 12.5, 15.1 and 9.8 letters; aflibercept met non-inferiority versus ranibizumab, with an adjusted difference of 2.23 letters and 95% confidence interval −2.17 to 6.63. 4

Bevacizumab did not demonstrate non-inferiority to ranibizumab: difference −1.73 letters, 95% confidence interval −6.12 to 2.67. This is an inconclusive non-inferiority comparison, not proof of inferiority; 407 of 463 attended at 100 weeks, and the analysis populations and missing-data methods matter. 4

BALATON enrolled 553 BRVO patients and COMINO 729 central or hemiretinal RVO patients. At 24 weeks, monthly faricimab was non-inferior to monthly aflibercept for visual gain: 16.9 versus 17.5 letters in BALATON and 16.9 versus 17.3 in COMINO. Greater absence of angiographic leakage was an anatomical secondary finding with nominal significance, not proof of superior vision or longer treatment intervals. 5

The current EU Eylea information includes 8 mg aflibercept for RVO, in 0.07 ml, as well as the separate 2 mg formulation in 0.05 ml. Concentrations, volumes and schedules are not interchangeable; the RVO regimen must not be borrowed from the AMD or diabetic-oedema section. 7

A recent myocardial infarction is a precaution requiring an individual benefit–risk discussion, not a blanket class contraindication established by the Eylea label. Its warning describes limited safety data after myocardial infarction, stroke or transient ischaemic attack within 6 months; it does not automatically make a steroid implant safer. 7

A dexamethasone implant can be an alternative when appropriate, with cataract and intraocular-pressure risks. The Ozurdex RVO indication differs from its restricted DME wording; advanced glaucoma uncontrolled by medicines and specified capsule/IOL configurations are contraindications. Lens status, capsular integrity, pressure response and follow-up therefore influence the choice. 1 2 8

PRP treats retinal ischaemia-related neovascular complications; it does not replace anti-VEGF treatment of macular oedema. In CVOS, immediate prophylactic PRP was not significantly better after adjustment for preventing the specified iris/angle new-vessel endpoint; that endpoint was not identical to established neovascular glaucoma. 6

CVOS randomised 90 eyes to early PRP and 91 to close observation. It supports careful iris and angle examination with prompt PRP when neovascularisation appears; absence of statistical significance does not prove equal outcomes. RCOphth also allows consideration of prophylactic PRP in selected high-risk eyes, particularly when reliable surveillance is difficult. 1 6

For BRVO, sector laser is relevant when retinal or disc new vessels develop; selected grid laser retains a possible role in macular oedema. The historical BVOS approach is therefore not simply obsolete, although injections are central in contemporary oedema care. 1

Expect repeated review and an individual treatment course. Some patients need therapy over 2 years or longer, but neither the original duration nor a single initial acuity or ischaemia measure determines every outcome; assess response, macular integrity and complications over time. 1 4

06Treat painful neovascular glaucoma as an emergency

Retinal ischaemia can drive iris and angle neovascularisation. A fibrovascular membrane may first impair an open angle and later contract into synechial closure; the term 90-day glaucoma is historical, not a reliable onset deadline. 1 9

Pain, redness, nausea, visual loss and corneal oedema with rubeosis demand immediate assessment. Pressures of 40–60 mmHg can occur, but neither a lower value nor the absence of a fixed threshold excludes a dangerous presentation. 9

Lower pressure and control inflammation while addressing the retinal ischaemic drive. Appropriate topical or systemic pressure-lowering medicines, a topical steroid and cycloplegia may be needed; anti-VEGF can rapidly regress new vessels, while retinal ablation provides a more sustained approach to the ischaemic stimulus. 1 9

Do not inject through uncontrolled pressure simply to follow a memorised sequence. The Eylea information says not to inject while pressure is at least 30 mmHg; assess pressure, optic nerve perfusion and the exact product before intervention. The original automatic paracentesis rule above 40 mmHg is not established by the reviewed guidance. 7 9

Anterior-chamber paracentesis can be a specialist procedural decision, not an obligatory first step for every NVG. The original 0.05 ml is an injection volume, not a universal dose or a reason that every eye must be tapped; 8 mg Eylea has a different volume. 7 9

Coordinate anti-VEGF and PRP according to visibility, pressure and clinical circumstances; anti-VEGF does not replace retinal treatment or continued surveillance. A drainage implant such as an Ahmed valve, filtering surgery in selected circumstances or cyclodestructive treatment may be required, depending on visual potential, pressure and comfort. 1 9

07Recognise arterial ischaemia even when central acuity is retained

CRAO can produce sudden profound painless visual loss, inner retinal whitening and a cherry-red spot. The relatively thin fovea permits the underlying choroidal colour to remain visible against swollen inner retina; the appearance is a clinical clue, not a requirement present in every arterial occlusion. 18

A patent cilioretinal artery arises from the ciliary circulation and may preserve the fovea. This explains acuity of 1.0 despite severe surrounding field loss; good central acuity does not exclude an arterial emergency. 18

Describe emboli cautiously: cholesterol Hollenhorst plaques are often refractile yellow, platelet–fibrin material is paler, and calcific emboli may be large and proximal. These appearances suggest a source rather than prove it; cardiac and carotid investigations follow the clinical arterial pathway. 18

Boxcarring describes segmented blood-column flow and must not be treated as proof that an embolus consists of platelet–fibrin. Record the embolus appearance, perfusion and symptoms separately; absence of a visible embolus does not establish or exclude an arteritic cause. 18

08Assess giant cell arteritis without delaying treatment

In retinal arterial occlusion, assess giant cell arteritis (GCA), particularly in adults over 50. The original threshold over 55 and requirement for no visible embolus are unsafe restrictions; also consider GCA in an appropriate anterior ischaemic optic neuropathy presentation. 18

Ask about new headache, jaw claudication and scalp or temporal tenderness, and examine for systemic and ocular ischaemic features. Check ESR, CRP and a blood count including platelets; markedly raised values support concern, but normal ESR and CRP do not completely exclude GCA. 13 18

When GCA is strongly suspected with threatened or established visual ischaemia, initiate urgent specialist systemic glucocorticoid treatment without waiting for imaging or biopsy. The purpose includes protecting the fellow eye; confirmation and further systemic treatment still matter. 13 18

EULAR recommends expert ultrasound of temporal and axillary arteries as first-line imaging for suspected GCA. A halo can support the diagnosis; MRI or FDG-PET may be alternatives, and temporal artery biopsy remains relevant when imaging is unavailable, inconclusive or inconsistent with the clinical picture. 13

The imaging recommendations combine a systematic evidence update with expert consensus. Availability and operator expertise affect applicability; they do not validate the original rigid age/embolus trigger or make a positive single test a complete clinical diagnosis. 13

09Use the emergency stroke pathway and explain thrombolysis uncertainty

Sudden symptomatic retinal arterial ischaemia requires immediate emergency assessment through the local stroke pathway, with ophthalmic confirmation and GCA assessment in parallel. Do not wait for the end of a 4.5-hour window, or defer later presenters because a potential reperfusion window has passed. 10 18

Routine ocular massage or anterior-chamber paracentesis has no established visual-restoration benefit in this setting and must not delay stroke assessment. This arterial treatment question is distinct from selected pressure management in NVG. 10 18

The AHA/ASA 2026 guideline still describes THEIA and TenCRAOS as ongoing or awaiting results at its evidence cutoff. Its publication year must not be mistaken for appraisal of subsequently published trial results; the following direct reports change what can be claimed about benefit. 10 11 12

THEIA randomised 70 patients with severe non-arteritic CRAO within 4.5 hours to intravenous alteplase or aspirin. Among the 56 with the primary outcome available, at least 0.3 logMAR improvement occurred in 19/29 versus 13/27; the unadjusted risk difference was 17.4 percentage points, with 95% confidence interval −11.8 to 46.5. 11

The adjusted odds ratio was 1.1, with 95% confidence interval 0.07–18.39; this is a different analysis from the raw response proportions. The small, underpowered trial, missing primary outcomes and very wide interval leave benefit uncertain; one asymptomatic intracranial haemorrhage does not establish safety. 11

TenCRAOS randomised 78 adults within 4.5 hours to tenecteplase or aspirin. At 30 days, acuity of at least 20/100 was reached in 8/40 versus 9/38; the risk difference was −3.7 percentage points, with 95% confidence interval −22.0 to 14.7 and P=0.69. One fatal intracranial haemorrhage occurred with tenecteplase. 12

These trials do not demonstrate routine visual benefit from systemic thrombolysis for CRAO and do not prove equivalence or rule out every possible subgroup effect. Any consideration belongs with an expert stroke team and the current protocol or research setting, after benefit–risk assessment; it must not be taught as a guaranteed AHA-backed rescue treatment. 10 11 12

Peri-event systemic vascular risk reinforces the need for urgent investigation and secondary prevention. Referral remains urgent without relying on one exact day or percentage; use the clinical arterial pathway and the findings of the systemic work-up. 10 18

10Locate PAMM in the middle retina and investigate the cause

Paracentral acute middle maculopathy (PAMM) is an OCT pattern of middle-retinal ischaemic injury, associated with the intermediate/deep capillary circulation. A band of INL hyperreflectivity may evolve into thinning; paracentral scotoma can persist despite good central acuity. 15 16

Inspect en-face structural OCT and the relevant B-scans, then look for arterial or venous disease and systemic precipitants. The original heading also says PAPA; its intended expansion remains unresolved rather than silently being replaced with a different disease. 15 16

The selected case series cannot establish that PAMM usually affects women or is specific to RVO. Treat the associated cause where identifiable and explain uncertainty about visual recovery; no treatment efficacy claim follows from these descriptive series alone. 15 16

11Present the finding, implication and next step

Use the comparison table to distinguish macular treatment from urgent arterial, arteritic and pressure-related problems. Sudden visual loss is assessed urgently before a label such as CRVO or BRVO is used to justify waiting days. 1 9 18

For each case, state what you observe, why it matters and the next examination or intervention. Explain the reason for the immediate decision and what needs checking at follow-up; the seven revision questions apply this sequence. 1 9 18

Present the finding, implication and next step
ConditionSymptomKey findingUrgencyManagement focus
CRVOPainless visual lossRetinal haemorrhages, possibly Blood & ThunderUrgent assessment of new loss; follow-up tailored to ischaemiaAnti-VEGF for relevant oedema; separate new-vessel surveillance
BRVOSectoral field defect or reduced central visionSectoral retinal haemorrhagesUrgent assessment of new loss; subsequent treatment individuallyOedema treatment; selected grid or sector laser for its specific indication
CRAOSudden profound visual loss; central acuity may be preservedInner retinal whitening, possible cherry-red spotImmediate emergency pathwayStroke-team assessment and GCA evaluation; no guaranteed thrombolysis benefit
GCAVisual ischaemia with or without typical systemic complaintsClinical suspicion, inflammatory tests and expert imagingImmediate treatment when strongly suspected with visual ischaemiaSystemic glucocorticoids without waiting for confirmatory tests
NVGPain, redness and reduced visionRubeosis and raised pressure, possibly above 40 mmHgImmediate specialist assessmentPressure/inflammation control, anti-VEGF and retinal ablation; selected surgery, no mandatory tap threshold
A patient with CRAO has visual acuity 1.0. How is that possible?

A patent cilioretinal artery may preserve the fovea while the surrounding retina and field are affected. This does not exclude an arterial emergency.

Why is routine prophylactic PRP not the default for every ischaemic CRVO?

CVOS did not demonstrate a significant adjusted reduction in its iris/angle new-vessel endpoint. Monitor closely and treat new vessels promptly; selected high-risk or poorly monitored eyes may still warrant prophylactic treatment under guideline-based specialist judgment.

Which clinical checks help before FA in suspected ischaemic CRVO?

Assess visual acuity and RAPD together with the fundus and anterior segment. The original acuity threshold of 0.1 is an orientation point, not a stand-alone diagnosis.

What should happen for painful NVG with pressure of 55 mmHg?

Immediate specialist pressure and perfusion assessment, pressure lowering and control of inflammation and retinal ischaemia. Paracentesis is a selected procedural option, not an automatic requirement before every injection; respect the exact product precautions.

A patient has cotton wool spots without diabetes. What should be investigated?

Review blood pressure and vascular history, blood disease such as severe anaemia, and clinically indicated infectious, inflammatory or irradiation-related causes. CWS are a retinal finding rather than a diagnosis requiring the same panel in every patient.

How long is anti-VEGF treatment needed for RVO-related oedema?

Some eyes need treatment for 2 years or longer, with individually adjusted intervals. Response and recurrence determine the course; surveillance for neovascularisation may remain necessary after oedema injections stop.

What helps estimate visual prognosis after RVO treatment?

Baseline visual function, macular perfusion and structural damage are relevant, together with treatment response and complications. There is no universally strongest single predictor or fixed individual outcome from the original summary alone.

References and access status

  1. 1
    RCOphth Retinal vein occlusion guideline, January 2022

    Selected extracted scope/method, clinical-summary/classification and systemic/PRP/follow-up sections read, including printed pages 1–11, 15 and 26–27. January 2022 document, review due January 2025; a 2026 URL does not make it a 2026 guideline. Full 51-page document, algorithms and cited studies not completely appraised. The original estimate that more than 90% are older than 55 remains unsupported; its exact population and primary source are pending.

  2. 2
    AAO Retinal Vein Occlusions PPP, 2024 / June 2026 update

    Official update/highlights and selected extracted PDF passages P315–316 and P322 read. June 2026 update includes US aflibercept 8 mg approval; local labels require separate inspection. Not a complete PPP, figure or reference appraisal.

  3. 3
    SCORE2 — Scott et al., 2017

    Complete indexed primary abstract and selected primary design passages read. Six-month randomised non-inferiority comparison; full report, protocol, masking, safety and missing-data assessment remain incomplete.

  4. 4
    LEAVO — Hykin et al., 2019

    Complete indexed primary abstract and selected NIHR scientific-summary/result-table passages read. Three-arm masked non-inferiority trial; full report, protocol, analysis populations and missing-data appraisal pending.

  5. 5
    BALATON / COMINO — Tadayoni et al., 2024

    Complete indexed primary abstract read. Monthly active-control comparisons through 24 weeks; full reports, non-inferiority margin/analyses, supplements and later switching-phase appraisal pending. Anatomical leakage results have nominal significance.

  6. 6
    CVOS Group N report, 1995

    Complete indexed primary abstract read. Early PRP versus observation; iris/angle new-vessel endpoint differs from established NVG. Full report, baseline adjustment, protocol and subgroup appraisal pending.

  7. 7
    EMA Eylea product information, accessed 5 November 2026

    Selected actual EU English product-information sections 4.1–4.4 for 2 mg and 8 mg formulations read. RVO indications, volume, scheduling and precautions checked; full label, current German document and QUASAR regulatory analysis not completely appraised.

  8. 8
    EMA Ozurdex product information

    Selected actual English PDF sections 4.1–4.4 read from the locally retained official document. RVO/DME wording, glaucoma/capsule contraindications and steroid risks distinguished. Fresh direct web retrieval returned 429; complete current-label revalidation remains pending.

  9. 9
    European Glaucoma Society, 6th edition — neovascular glaucoma

    Actual selected neovascular-glaucoma section II.2.5.2.1, printed page 152, read. Pressure/inflammation, anti-VEGF/retinal ablation and surgical options checked; not a complete textbook appraisal or validation of a universal paracentesis threshold.

  10. 10
    AHA/ASA acute ischaemic stroke guideline, 2026

    Selected indexed CRAO evidence-gap passages read; direct retrieval returned 403. Its trial-status wording reflects the writing cutoff and does not appraise later THEIA/TenCRAOS results. Full guideline and exact recommendation tables remain pending.

  11. 11
    THEIA — Préterre et al., 2025

    Complete indexed primary abstract read. Randomised masked/double-dummy comparison with missing primary outcomes and imprecision; full paper, protocol, statistical plan and later correspondence remain unread.

  12. 12
    TenCRAOS — Ryan et al., 2026

    Complete indexed primary abstract read. Randomised double-blind double-dummy comparison; small sample and wide confidence interval, with a fatal intracranial haemorrhage. Full paper, protocol, statistical plan and supplement remain unread.

  13. 13
    EULAR large-vessel vasculitis imaging recommendations, 2023 update

    Complete indexed abstract and selected indexed primary overarching-principle/ultrasound passages read. Systematic update plus expert consensus; direct journal retrieval returned 403. Full methods, evidence tables and supplements remain pending.

  14. 14
    DOG/RG/BVA S2e retinal arterial occlusions, October 2022

    Official catalogue entry and selected indexed PDF excerpts located. Download returned HTML access denial, not the guideline PDF. No full clinical appraisal or current German recommendation verification claimed.

  15. 15
    Perivenular PAMM — Falavarjani et al., 2017

    Complete indexed primary abstract read. Retrospective selected 11-eye series with en-face structural OCT pattern; not a diagnostic-accuracy, prevalence or treatment trial. Full report and image appraisal pending.

  16. 16
    Widefield en-face OCT in incomplete RAO, 2021

    Complete indexed primary abstract read. Three selected patients; pattern described with presumed incomplete arterial occlusion and unremarkable FA. Full report, image appraisal and validation remain pending.

  17. 17
    WHO EMRO Unified Medical Dictionary

    Selected actual English–Arabic entries inspected on 5 November 2026: neovascular glaucoma, cotton-wool spots, giant cell arteritis, aqueous paracentesis, paracentesis, inner nuclear layer and retinal vein. Several exact compound queries returned no result; that is not proof of global absence. See terminology ledger; no blanket dictionary or clinical-translation approval.

  18. 18
    AAO Retinal and Ophthalmic Artery Occlusions PPP, 2024

    Actual official PDF retrieved; selected extracted clinical passages read, including P280–283, P286–287 and acute management. Not a complete PPP or visual figure appraisal. The original 20–30% cilioretinal population claim differs from the 15–25% macula-perfusing-eye description; denominators and primary anatomical sources remain unresolved. The original first-7-days risk source also remains pending.

  19. 19
    EMA Vabysmo — official medicine overview

    Official EMA overview indications and RVO-study summary read on 5 November 2026. Supports EU RVO indication for faricimab; full current product information, local procedural details and complete regulator assessment remain pending. The later common-treatment phase is not continued randomised head-to-head evidence.

Original lecture links